For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA Network Open.
This article was originally published on MedicalXpress.com
For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA Network Open.
This article was originally published on MedicalXpress.com
© 2024 SimplyWell.ca